-$1.20 EPS Expected for Catalyst Biosciences Inc (NASDAQ:CBIO) This Quarter

Share on StockTwits

Analysts forecast that Catalyst Biosciences Inc (NASDAQ:CBIO) will report earnings per share of ($1.20) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings of ($0.54) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 122.2%. The firm is scheduled to report its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Catalyst Biosciences will report full year earnings of ($4.88) per share for the current fiscal year. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.18).

Separately, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

Several hedge funds and other institutional investors have recently bought and sold shares of CBIO. Nantahala Capital Management LLC bought a new stake in shares of Catalyst Biosciences during the 4th quarter worth $6,748,000. Dimensional Fund Advisors LP lifted its holdings in shares of Catalyst Biosciences by 25.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 508,232 shares of the biopharmaceutical company’s stock worth $4,010,000 after acquiring an additional 103,874 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Catalyst Biosciences by 40.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 288,600 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 83,701 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Catalyst Biosciences by 1,127.7% during the 4th quarter. Bank of America Corp DE now owns 58,559 shares of the biopharmaceutical company’s stock worth $462,000 after acquiring an additional 53,789 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Catalyst Biosciences by 4.8% during the 4th quarter. BlackRock Inc. now owns 846,529 shares of the biopharmaceutical company’s stock worth $6,680,000 after acquiring an additional 39,088 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

NASDAQ:CBIO traded down $0.01 during trading hours on Friday, hitting $8.42. The stock had a trading volume of 710 shares, compared to its average volume of 348,757. The business’s 50 day moving average price is $7.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 24.94 and a quick ratio of 24.94. Catalyst Biosciences has a one year low of $6.20 and a one year high of $13.36. The stock has a market cap of $103.15 million, a price-to-earnings ratio of -3.15 and a beta of 2.19.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Further Reading: Put Option

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Macquarie Downgrades Viacom  to Neutral
Macquarie Downgrades Viacom to Neutral
Contrasting Toshiba  & The Competition
Contrasting Toshiba & The Competition
Head to Head Survey: Fanhua  & Its Competitors
Head to Head Survey: Fanhua & Its Competitors
Head-To-Head Survey: Landstar  & Braskem
Head-To-Head Survey: Landstar & Braskem
Deutsche Bank Lowers Deere & Company  Price Target to $155.00
Deutsche Bank Lowers Deere & Company Price Target to $155.00
OMV  Downgraded by Goldman Sachs Group to Neutral
OMV Downgraded by Goldman Sachs Group to Neutral


 
© 2006-2019 Zolmax.